IL33 and immunoglobulin G4-related sclerosing disease: Targeting the IFN-I-IL-33 axis in pDCs might constitute a successful approach to treat patients with AIP and IgG4-RD, especially those who suffer from repeated episodes of relapse even with PSL treatment or side effects associated with PSL.